Press Releases News Year None202020192018201720162015201420132012 Ophthotech Announces Strategic Review Plan Feb 01, 2017 | Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration Dec 12, 2016 | Ophthotech Reports Third Quarter 2016 Financial and Operating Results Nov 08, 2016 | Ophthotech Announces the Publication of Fovista® in Combination with Lucentis® Phase 2b Study Results in Ophthalmology®, the Journal of the American Academy of Ophthalmology Oct 31, 2016 | Ophthotech Corporation to Report Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 8, 2016 Oct 24, 2016 | Ophthotech Corporation to Present at the Morgan Stanley Global Healthcare Conference Sep 06, 2016 | Ophthotech Reports Second Quarter 2016 Financial and Operating Results Aug 03, 2016 | Ophthotech Announces Election of Ian F. Smith, Vertex Executive Vice President and Chief Financial Officer, to Its Board of Directors Aug 02, 2016 | Ophthotech Corporation to Report Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016 Jul 25, 2016 | Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDGF Therapy in Combination with Eylea® or Avastin® in Wet Age-Related Macular Degeneration Jun 20, 2016 | Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last »
Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration Dec 12, 2016 |
Ophthotech Announces the Publication of Fovista® in Combination with Lucentis® Phase 2b Study Results in Ophthalmology®, the Journal of the American Academy of Ophthalmology Oct 31, 2016 |
Ophthotech Corporation to Report Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 8, 2016 Oct 24, 2016 |
Ophthotech Announces Election of Ian F. Smith, Vertex Executive Vice President and Chief Financial Officer, to Its Board of Directors Aug 02, 2016 |
Ophthotech Corporation to Report Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016 Jul 25, 2016 |
Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDGF Therapy in Combination with Eylea® or Avastin® in Wet Age-Related Macular Degeneration Jun 20, 2016 |
Press Releases News Year None202020192018201720162015201420132012 Ophthotech Announces Strategic Review Plan Feb 01, 2017 | Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration Dec 12, 2016 | Ophthotech Reports Third Quarter 2016 Financial and Operating Results Nov 08, 2016 | Ophthotech Announces the Publication of Fovista® in Combination with Lucentis® Phase 2b Study Results in Ophthalmology®, the Journal of the American Academy of Ophthalmology Oct 31, 2016 | Ophthotech Corporation to Report Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 8, 2016 Oct 24, 2016 | Ophthotech Corporation to Present at the Morgan Stanley Global Healthcare Conference Sep 06, 2016 | Ophthotech Reports Second Quarter 2016 Financial and Operating Results Aug 03, 2016 | Ophthotech Announces Election of Ian F. Smith, Vertex Executive Vice President and Chief Financial Officer, to Its Board of Directors Aug 02, 2016 | Ophthotech Corporation to Report Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016 Jul 25, 2016 | Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDGF Therapy in Combination with Eylea® or Avastin® in Wet Age-Related Macular Degeneration Jun 20, 2016 | Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page next › Last page last »
Ophthotech Announces Results from Pivotal Phase 3 Trials of Fovista® in Wet Age-Related Macular Degeneration Dec 12, 2016 |
Ophthotech Announces the Publication of Fovista® in Combination with Lucentis® Phase 2b Study Results in Ophthalmology®, the Journal of the American Academy of Ophthalmology Oct 31, 2016 |
Ophthotech Corporation to Report Third Quarter 2016 Financial Results and Host Conference Call on Tuesday, November 8, 2016 Oct 24, 2016 |
Ophthotech Announces Election of Ian F. Smith, Vertex Executive Vice President and Chief Financial Officer, to Its Board of Directors Aug 02, 2016 |
Ophthotech Corporation to Report Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016 Jul 25, 2016 |
Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista® Anti-PDGF Therapy in Combination with Eylea® or Avastin® in Wet Age-Related Macular Degeneration Jun 20, 2016 |
